This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Allogene Therapeutics’s 8K filing here.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Recommended Stories
- Five stocks we like better than Allogene Therapeutics
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Steel Stocks Soaring After Tariff Announcements
- Ride Out The Recession With These Dividend Kings
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Why Salesforce Stock Could Be at Fresh Highs by February
